M
Mimi I. Hu
Researcher at University of Texas MD Anderson Cancer Center
Publications - 84
Citations - 2629
Mimi I. Hu is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medullary thyroid cancer & Thyroid cancer. The author has an hindex of 24, co-authored 78 publications receiving 1864 citations. Previous affiliations of Mimi I. Hu include Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
Vivek Subbiah,Justin F. Gainor,Rami Rahal,Jason D. Brubaker,Joseph L. Kim,Michelle Maynard,Wei Hu,Qiongfang Cao,Michael Sheets,Douglas Wilson,Kevin J. Wilson,Lucian DiPietro,Paul Fleming,Michael Palmer,Mimi I. Hu,Lori J. Wirth,Marcia S. Brose,Sai-Hong Ignatius Ou,Matthew H. Taylor,Elena Garralda,Stephen D. Miller,Beni B. Wolf,Christoph Lengauer,Timothy Guzi,Erica Evans +24 more
TL;DR: First-in-human testing of BLU-667 significantly inhibited RET signaling and induced durable clinical responses in patients with RET-altered NSCLC and MTC without notable off-target toxicity, providing clinical validation for selective RET targeting.
Journal ArticleDOI
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Vivek Subbiah,Mimi I. Hu,Lori J. Wirth,Martin Schuler,Aaron S. Mansfield,Giuseppe Curigliano,Marcia S. Brose,Viola W. Zhu,Sophie Leboulleux,Daniel W. Bowles,Christina S. Baik,Douglas Adkins,Bhumsuk Keam,Ignacio Matos,Elena Garralda,Justin F. Gainor,Gilberto Lopes,Chia-Chi Lin,Yann Godbert,Debashis Sarker,Stephen G. Miller,Corinne Clifford,Hui Zhang,Christopher D. Turner,Matthew H. Taylor +24 more
TL;DR: The ARROW trial as discussed by the authors evaluated the safety and antitumour activity of pralsetinib, a highly potent, selective RET inhibitor, in patients with RET-altered thyroid cancers.
Journal ArticleDOI
Denosumab for treatment of hypercalcemia of malignancy.
Mimi I. Hu,Ilya G. Glezerman,Sophie Leboulleux,Karl L. Insogna,Rasim Gucalp,Waldemar Misiorowski,Bennett Yu,Paul Zorsky,Diego Tosi,Alberto Bessudo,Arnaud Jaccard,Giuseppe Tonini,Wendy Ying,Ada Braun,Rajul K. Jain +14 more
TL;DR: In patients with HCM despite recent iv bisphosphonate treatment, denosumab lowered serum calcium in 64% of patients within 10 days, inducing durable responses and may offer a new treatment option for HCM.
Journal ArticleDOI
Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
Priyanka C. Iyer,Maria E. Cabanillas,Steven G. Waguespack,Mimi I. Hu,Sonali Thosani,Victor R. Lavis,Naifa L. Busaidy,Sumit K. Subudhi,Adi Diab,Ramona Dadu +9 more
TL;DR: IrT manifests as an early onset of thyrotoxicosis, which is largely asymptomatic, followed by rapid transition to hypothyroidism requiring long-term levothyroxine substitution, and the evolution of irT is more rapid with combination ICI.
Journal ArticleDOI
Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience.
Shamim Ejaz,Rena Vassilopoulou-Sellin,Naifa L. Busaidy,Mimi I. Hu,Steven G. Waguespack,Camilo Jimenez,Anita K. Ying,Maria E. Cabanillas,Maher Abbara,Mouhammed Amir Habra +9 more
TL;DR: The authors have described their experience with CS‐EAS at The University of Texas MD Anderson Cancer Center to further enhance the current understanding and management of this syndrome.